Efimosfermin is a phase III-ready, potential best-in-class, investigational specialty medicine to treat and prevent progression of steatotic liver disease (SLD). Under the agreement, GSK will pay $1.2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results